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Abstract 
Purpose: Approximately 800,000 safety reports are submitted to the FDA annually, however, only significant issues generate drug 
safety communications (DSC). The purpose of this study was to determine the type of clinical evidence used to warrant a change in 
drug labeling for drugs with DSC between January 1, 2010 and December 31, 2014.  Methods: Selected data was obtained from the 
FDA website. The primary endpoint of the study was the frequency of the types of clinical evidence used in FDA communications, as 
reported through the FDA DSC.  Results were evaluated via descriptive statistics, and chi-squared for nominal data. Results:  A total of 
2521 drug safety labeling changes were identified and 99 (3.9%) of safety communications met the inclusion criteria.  The majority of 
the labeling changes were associated with single agents (83.8%). The three most frequently reported labeling changes were warnings 
(68.7%), precautions (58.6%), and patient package insert/medication guide (23.2%).  Case reports resulted in the greatest number of 
documented literature types (n = 791), followed by randomized controlled trials (n = 76), and case control/cohort studies (n = 74).   
Significantly more evidence for DSCs were classified as Level of Evidence B (LOE B, 68.6%), compared to LOE A (17.1%), and LOE C 
(14.1%) (p = 0.007). Conclusions: The majority of drug labeling change initiators was associated with LOE equivalent to B.  Practitioners 
should evaluate data associated with labeling changes to determine how to interpret the information for their patients. 
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Introduction 
The Food and Drug Administration is tasked with protecting 
the public health from safety risks associated with medications 
and other products.1 Clinical trial information is extensively 
reviewed prior to market approval and postmarketing safety 
reports are used to ensure that harm is not disproportionately 
reflected in patient outcomes.  New drugs are approved on the 
market faster now than ever before. The number of drugs that 
were approved in 2014 doubled the number approved in 
2008.2,3 The FDA is able to approve drugs with more efficiency 
due to updated conditions and regulations that mandate drug 
companies conduct follow up studies after approval of their 
drug.4 New information can emerge about the safety of a drug 
as a result of postmarketing surveillance studies and voluntary 
MedWatch safety reports.  
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Approximately 800,000 safety reports are submitted to the 
FDA yearly.5 Clinically significant safety information is 
conveyed to the public through written communications, 
broadcasts, webinars, conference calls, various forms of 
electronic social media, and the FDA website.6 Drug Safety 
Communications (DSC) are electronic documents used to 
communicate important safety information to the public.7   
This format was established in early 2010 to improve the 
clarity of communications from FDA to the public.  DSCs 
commonly consists of a summary of the safety issue, nature of 
the risk, established benefits of the particular drug or drug 
class, recommendations for health care providers and 
patients, and a summary of the data reviewed by the FDA.6 
DSCs can result from labeling target populations in which the 
drug should be used, adverse effects, drug-drug interactions, 
contraindications, warnings and precautions, and patient 
package inserts or medication guides.6 These safety alerts are 
intended to inform patients, as well as, assist healthcare 
providers make the most informed decisions regarding drug 
therapy.  No information exists to document that patients read 
these reviews. 
 
DSCs use clinical evidence to justify changes that are made on 
drug labels. However, the level of clinical evidence associated 
with each communication is not standardized and can vary 
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(e.g., single adverse drug reactions to controlled clinical trial).8 
Unfortunately, drug safety communications that result from 
preliminary information may cause patients to discontinue 
needed medications or alter the way in which the medication 
may be taken that is not consistent with the way in which the 
drug was prescribed.  In addition, physicians may opt to 
discontinue needed therapy, depending on the risk associated 
with continuing therapy.9  Premature warnings could result in 
unnecessary reluctance among physicians to prescribe a 
particular drug. On the other hand, safety alerts can prevent 
adverse effects and negative health outcomes among high-risk 
patients. Therefore, to provide optimal patient care and to 
avoid unsubstantiated changes in therapy, it is essential to be 
able to determine the clinical evidence associated with 
labeling changes and to determine how that information 
should be used in defined patient populations.10 
 
Lester et al evaluated safety-related drug label changes in 
2010.11  In this study, spontaneous reports were associated 
with 52% and 55% of label changes and anti-infectives and 
cardiovascular drugs were among the drug classes most 
frequently affected.  The label change initiator was most 
commonly associated with adverse reactions, precautions, and 
warnings.11 These findings are consistent with a previous study 
in which over half of the adverse events were associated with 
spontaneous reports and 25% were associated with 
information from clinical trials.12 
 
Currently, there is a lack of published literature that describes 
the level of evidence associated with labeling changes that are 
reported via FDA DSCs. The purpose of this retrospective study 
was to determine the type of clinical evidence used to warrant 
a change in drug labeling for drugs with FDA drug safety 
communications from January 1, 2010 to December 31, 2014.   
 
Methods 
This study was a retrospective data analysis evaluating FDA 
DSCs and the level of evidence used to warrant drug label 
changes.  FDA DSCs posted from January 1, 2010 to December 
31, 2014 were analyzed in this study.  The primary endpoint 
was the frequency of types of clinical evidence used in the FDA 
drug safety communications as reported in the 
communication.  Secondary endpoints were the type of drug 
labeling changes made (e.g. boxed warning, contraindication, 
warnings, precautions, dosage administration, drug 
interactions, adverse events, patient package 
insert/medication guide, pregnancy category, other changes).   
 
All FDA drug safety communications from 2010 to 2014 
involving a label change were included in the study.  Updates 
to safety communications were included if the update 
consisted of a label change.  Updated safety communications 
that met the inclusion criteria were recorded in the year that 
the original labeling change was made.  Safety 
communications for over-the-counter (OTC), blood, and tissue 
products were excluded.  On-going safety communications 
that had not yet resulted in a label change were also excluded.  
Radiopharmaceuticals, contrast agents, and other products 
that were not recognized by American Hospital Formulary 
Service (AHFS) were not included in the study. 
 
Selected data was obtained from the Drug Safety and 
Availability section of the FDA website 
(http://www.fda.gov/Safety/MedWatch/SafetyInformation/d
efault.htm).13 Drug communication entries included the 
following information: safety announcement, additional 
information for patients and healthcare professionals, and the 
data summary.  Data was sorted by date of the FDA 
communication and extracted from this website between April 
and June of 2015.   
 
The data was compiled and sorted into an Excel spreadsheet.  
The initial draft of the spreadsheet was pilot tested with five 
products to determine which variables needed to be included 
in the spreadsheet.  The data was manually evaluated to 
include the following information: date of the safety 
communication, AHFS classification, drug or drug class 
involved, type of label change (e.g. boxed warnings, 
contraindications, warnings, precautions, dosage 
administration, drug interactions, adverse reactions, patient 
package insert/medication guide, pregnancy category, and 
other changes), the level of evidence, type of study/evidence 
used to support the change, whether the data was published, 
and if the safety communication was ongoing.  The type of 
label change was extracted from the safety announcement 
component.  When the safety announcement was unclear as 
to the rationale of the label change, the package insert was 
consulted for recent changes.  If two drugs in the same safety 
alert had different AHFS categories, the merged category was 
included in the data analysis.  Addition of a medication guide 
was recorded as changes to the medication guide.  The data 
summary section provided the information related to the type 
of evidence used to support the label change.  If literature type 
could not be determined from the drug safety communication, 
the manuscript abstracts were searched through PubMed to 
determine the type of study for appropriate classification.  
Consensus between investigators was maintained when 
PubMed searches were completed.  
 
Level of evidence (LOE) was determined based on the criteria 
from the American College of Cardiology and American Heart 
Association (ACC/AHA) guidelines.14 The evidence was 
classified by Levels A – C.  Level A evidence consisted of data 
from multiple (n ≥ 2) randomized clinical trials (RCTs) or a 
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single meta-analysis (MA).  A single randomized clinical trial, 
non-randomized studies (e.g. cohort studies, case-control 
studies), or any registry or database evaluations (e.g. FDA 
Adverse Event Reporting System) were classified as Level B 
evidence.  Level C evidence included any expert opinions, case 
studies, or case reports.  Spontaneous case reports were 
included as Level C evidence.  Communications that did not 
include any evidence or include the types of evidence used 
were automatically recorded as Level C evidence.  If more than 
one type of evidence was cited in the safety communication, 
then the highest level of evidence was documented.   
 
Pooled-analysis were classified as meta-analyses.  If the FDA 
drug safety communication indicated “several” case reports 
were documented and did not include the exact number of 
case reports, then the Merriam-Webster’s definition of 
“several” to be “more than 2” was used to assign a value of 3 
in the spreadsheet.15 Clinical evidence was recorded as 
published if the communication stated it was published or the 
article was found to be published through the reference listed. 
 
Results were evaluated by descriptive and inferential statistics.  
Descriptive statistics were used to quantify the following data:  
number of FDA safety communications issued per year was 
calculated, mean number of clinical literature by literature 
type (e.g. tallied number of: meta-analysis, randomized 
controlled clinical trials, registries, cohorts, case series, and 
case reports). Pearson Chi-square test was used to evaluate 
nominal data (e.g., associations between LOE and year of 
labeling change, type of labeling change, publication status, 
AHFS class, number of single agents and drug classes, etc).  
Proportions or cross-tabulations of frequency data were also 
conducted.  Analysis was performed using SPSS version 19 
(Armonk, NY).   
 
Results 
A total of 2,521 label changes were identified between years 
2010 and 2014.  However, only 142 data safety 
communications were evaluated and 99 met the criteria for 
the study.  Forty-three of the DSCs were excluded because of 
their OTC status (n=6), communication did not result in a label 
change (n=35) or the product was not in the AHFS (n=2).  The 
largest amount of exclusions was in 2012 (n=10), followed by 
2011 (n=9), and 2010 and 2013 (n=8, respectively).   
See Figure 1. 
 
The following DSCs were included, as reflected by the year:  
2010 (n=20), 2011 (n=33), 2012, 2013 (n=19), and 2014 (n=8).   
The 75 drugs and 12 drug classes within the safety 
communications were from 21 AHFS classifications.  The top 
three most common classifications were central nervous 
system drugs, anti-infective agents, and cardiovascular drugs 
and consisted of 21, 18, and 9 communications, respectively.  
Of the 99 communications 16 (16.2%) were in reference to an 
entire drug class (see table 1).  The three most common 
changes were in the categories of warnings, precautions, or 
patient package insert/medication guide which were found in 
68 (68.7%), 58 (58.6%), and 23 (23.2%) communications, 
respectively.  Only 17 (17.2%) communications lead to changes 
to boxed warnings.   
 
Drug safety communications were most commonly associated 
with level B evidence.  There were 17 communications 
classified as level A, 68 communications categorized as level B, 
and 14 communications were level C.  The most abundant 
source of evidence was case reports, which had a total of 791 
entries.  Registries consisted of 41 queries that lead to 38 
changes.  In total, 42 communications referenced evidence 
that was published within the literature (see table 2). 
 
Differences between LOE of the single agents used in the DSC 
was compared for the level of evidence and no significant 
differences were identified for single agents and LOE involved 
for the DSCs; (P=0.497. However, a significant difference 
between LOE and AHFS drug classes was observed (p=0.007).   
Of the top three drug classes, the percentage of DSCs in the 
central nervous system drugs classified with LOE A, B, and C 
was 17.6%, 26.5%, and 0%, respectively.  In the anti-infective 
agent class, the percentage of DSCs classified as LOE A, B, and 
C, were 11.8%, 19.1%, and 21.4%, respectively.  The 
percentage of DSCs identified in cardiovascular drugs as LOE A, 
B, and C was 17.6%, 26.5%, and 0%, respectively (see tables 1 
and 2).   
 
The percentage of unpublished data with LOE A, B, and C 
evidence was 47.1%, 52.9%, and 92.9%, respectively, 
compared to the same LOE type in the published data set 
(52.9%, 47.1%, and 7.1%, respectively).   Therefore, a 
statistically significant inverse relationship between 
publication and LOE (p = 0.002) was observed which indicated 
that published reports were associated with fewer robust 
literature classifications, with the exception of LOE A (Table 3).  
No statistically significant associations between published 
reports and label classifications (e.g., boxed warnings, 
contraindications, warnings, precautions, dosage 
administration, patient package insert/medication guide, 
pregnancy, or other) were observed.  However, fewer DSCs 
that provided information on drug-drug interactions were 
published compared to those label changes that were not 
associated with drug-drug interactions (11.9% vs. 88.1%; 
p=0.048).  Similarly, significantly fewer label changes for 
adverse events were published compared to other label 
change categories (2.4% vs. 97.6%; p=0.016) (Table 3).  
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Discussion 
The majority of evidence used to warrant a change in drug 
labeling for drugs that had FDA safety communications over 
the five-year period was associated with Level B evidence.  
Central nervous system, anti-infective, and cardiovascular 
drugs were associated with the largest number of FDA DSCs 
with labeling changes.  In addition, the warnings section of the 
package insert was more frequently associated with changes.    
 
Rackham et al. evaluated the evidence supporting FDA alerts 
for drugs with adverse cardiovascular events. Nine drug safety 
communications were included in the review and the strength 
of evidence was ranked according to Level of evidence A, B, C, 
and U (unrated). Of the nine, only one safety alert was 
classified as level A evidence with the majority of evidence 
being presented as cohorts, case controls, case reports/case 
series, expert opinions or anecdotal evidence.10  
 
Studies and other important patient-related information have 
the ability to impact regulatory decisions regarding drug 
products.  All of them may not be associated with the best 
clinical evidence. Moore et al. evaluated safety warnings in 
2009 and found that adverse event reports by either drug 
manufacturers or through the MedWatch program influenced 
the majority of the FDA’s new regulatory actions and new 
boxed warnings, 57% and 76% respectively. Clinical studies 
only represented 26 of the 135 changes (19%), but only two 
were derived from statistically significant differences and one 
was based on a single study case.4 
  
The clinical impact of FDA communications on patient care has 
been evaluated.  Clinical care was significantly impacted as 
antipsychotic and antidepressant communications were 
associated with a decrease use in non-targeted populations 
and an increase in suicides among children following the 
antidepressant advisories.16 
 
Our study demonstrates that the level of evidence that 
prompts FDA drug safety communications is not consistent 
with the rigor of controlled clinical trials. However, controlled 
clinical trials are not the best way to evaluate adverse drug 
reactions associated with drug products. This study confirms 
that LOE B is associated more frequently with labeling changes.  
Previous studies have evaluated drug safety label changes over 
short periods of time compared to our comparison over a 5-
year period.  Furthermore, to our knowledge this is the only 
study that evaluated the association between label changes 
and LOE used in corresponding safety communications.  In 
addition, the current study evaluated drug safety 
communications, the information that is most readily available 
to health care professionals and the public regarding safety 
topics that are deemed most important by the FDA.  Despite 
this, no significance was found between type of label change 
initiator and LOE.  There was also no significant difference 
between the LOE of the clinical information and 5-year period 
associated with the study.  A relationship was found between 
AHFS class and LOE, but it was not determined if one 
classification tended to have better evidence compared to 
another.  Lastly, an inverse relationship was observed between 
publication and LOE which seems to indicate that safety 
concerns with more publications tended to be less likely to 
have a drug safety communication. Spontaneous reporting 
appears to be the most common literature type associated 
with label changes.  Although spontaneous communications 
are useful in helping practitioners hypothesize important 
information about drug products, they are limited in their 
ability to determine the magnitude of clinical impact the label 
change initiator may have.  In addition, underreporting and 
insufficient clinical information limits the usefulness of this 
type of literature. 19 
 
The clinical impact of drug safety communications may be far 
reaching and unpredictable.  Communications for targeted 
populations may have an exaggerated effect on other 
subpopulations. There may be a large decrease in utilization 
that may inappropriately impact patients.  As a result, 
practitioners need to be able to determine the risk:benefit 
profile in their patients in order to recommend appropriate 
therapeutic strategies in light of FDA safety communications.   
 
The study contained several limitations. The quality of the data 
(e.g., meta-analysis, controlled clinical trials) used for each 
therapeutic classification was not analyzed.  Furthermore, our 
assessment did not take into account the quantity of evidence 
presented under categories B or C.  The sample size of this 
study is small and therefore limits the number of relationships 
that can be discerned from the data. When a communication 
was in reference to two or more drugs, but not a drug class, all 
drugs and evidence were combined as a single entry.  This 
method prevented proper association between evidence and 
its corresponding drug. The method in which data was 
tabulated restricted the number of tests that could be 
performed.  This prevented stratification of data within a set 
to determine if associations could be made between 
subgroups and factors such as LOE. If it was not possible to 
determine the type of data used to impose a labeling change, 
then it was automatically assigned to level C.  This may have 
had a small impact on the findings. Selection bias could be 
introduced based on how the investigators chose to interpret 
a communication in light of the inclusion criteria. An effort was 
made to minimize such bias through active communication 
between investigators in order to maintain consensus. 
Communications had varying depths and information was 
provided in a different format than other communications 
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within the same year. Although the investigators could have 
contacted the FDA to determine whether or not additional 
information was used to initiate safety alerts, the purpose of 
the study was to evaluate drug safety communications and 
investigators deemed additional probing of the FDA was 
unwarranted.  These communications are those that the FDA 
deems as most important.  In addition, pooled analysis was 
considered meta-analyses; however, due to the small size of 
these analyses (n=9; 0.9%), it is unlikely that this assessment 
affected the results. 
 
Conclusion 
Drug safety communications are released to the public for 
safety information that will most frequently impact patient 
care.  However, only a fraction of the drug labeling changes 
prompt a drug safety communication.  This analysis revealed 
that the majority of literature associated with labeling changes 
resulted from Level of Evidence B (i.e., single, randomized trial, 
non-randomized studies, and registry or database 
evaluations).  In addition, the most frequent type of drug 
labeling changes was due to warnings, precautions, and 
patient package insert/medication guide; however, no 
statistically significant differences were observed between 
type of drug labeling changes and level of evidence.  Although 
the level of evidence associated with labeling changes was not 
considered the most robust literature type available, 
practitioners need to be able to evaluate this type of data to 
determine the potential impact in their patient population.  
Additional studies are warranted to determine the quality of 
the evidence of all drug labeling changes to determine the 
level of evidence associated with each.   
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     Figure 1:  Inclusion/Exclusion Flow Chart 
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Total 
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DSC-drug safety communication; OTC-over the counter; AHFS-American Hospital Formulary Service 
Safety alerts identified 
(n=2521) 
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Table 1: Frequency of Safety Communication Characteristicsa 
 
Characteristic Frequency (%) 
Year 
2010 20 (20.2) 
2011 33 (33.3) 
2012 19 (19.2) 
2013 19 (19.2) 
2014 8 (8.1) 
Single agent 83 (83.8) 
Drug Class 16 (16.2) 
AHFS drug classification 
Anorexigenic agent 1 (1.0) 
Bone resorption inhibitors 2.0 (2.0) 
Immunosuppresive Agents 8 (8.1) 
Local anesthetics 1 (1.0) 
Other Misc. Therapeutic Agents 2 (2.0) 
5-Alpha Reductase Inhibitors 1 (1.0) 
Anti-Infective Agents 18 (18.2) 
Antidotes 1 (1.0) 
Antineoplastic Agents 6 (6.0) 
Autonomic Drugs 5 (5.1) 
Blood Formation and Coagulation 6 (6.1) 
Cardiovascular Drugs 9 (9.1) 
Central Nervous System Drugs 21 (21.2) 
Electrolytic, caloric, and water balance 1 (1.0) 
Expectorants and Cough Preparations  2 (2.0) 
Gastrointestinal Drugs 6 (6.1) 
Gold Compounds 2 (2.0) 
Hormones 4 (4.0) 
Anti-infective agents, Cardiovascular drugs 1 (1.0) 
Diagnostic agent, Cardiovascular drugs 1 (1.0) 
Immunosuppressive agents, Antineoplastic agents 1 (1.0) 
Safety classification 
Boxed warning 17 (17.2) 
Contraindication 17 (17.2) 
Warnings 68 (68.7) 
Precautions 58 (58.6) 
Dosage administration 15 (15.2) 
Drug interactions 6 (6.1) 
Adverse reactions 11 (11.1) 
Patient Package Insert/Medication Guide 23 (23.2) 
Pregnancy 7 (7.1) 
Other changes 20 (20.2) 
Meta-analysis 9 (0.9) 
Randomized controlled trials 76 (7.6) 
Registry 43 (4.3) 
Case Control/Cohort 74 (7.4) 
Case Series 3 (0.3) 
Case Report 791 (79.0) 
Expert Opinion  5 (0.5) 
aPercentages could add up to greater than 100%  
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Table 2:  Communication Characteristics vs. Level of Evidence (%) 
 
Safety Characteristic LOE A (n = 17) 
LOE B 
(n = 68) 
LOE C 
(n = 14) 
Total p 
Year      
2010 2 (11.8) 13 (19.1) 5 (35.7) 20 (20.2)  
2011 6 (35.3) 23 (33.8) 4 (28.6) 33 (33.3)  
2012 4 (23.5) 12 (17.6) 3 (21.4) 19 (19.2)  
2013 4 (23.5) 14 (20.6) 1 (7.1) 19 (19.2)  
2014 1 (5.9) 6 (8.8) 1 (7.1) 8 (8.1)  
Single Agent 13 (76.5) 59 (86.5) 11 (78.6) 83 (83.8) 0.306 
Drug class 4 (23.5) 9 (13.2) 3 (21.4) 16 (6.2) 0.306 
Published 9 (52.9) 32 (47.1) 1 (7.1) 42 (42.4) 0.002 
AHFS Classification      
Anorexigenic agent 0 (0.0) 1 (1.5) 0 (0.0) 1 (1)  
Bone resorption inhibitors 0 (0.0) 2 (2.0) 0 (0.0) 2 (2.0)  
Immunosuppressive Agents 1 (5.9) 2 (2.9) 5 (35.7) 8 (8.1)  
Local anesthetics 0 (0.0) 1(1.5) 0 (0.0) 1 (1.0)  
Other Misc. Therapeutic  Agents                                        0 (0.0) 2 (2.9) 0 (0.0) 2 (2.0)  
5-Alpha Reductase Inhibitors 1 (5.9) 0 (0.0) 0 (0.0) 1 (1.0)  
Anti-Infective Agents 2 (11.8) 13 (19.1) 3 (21.4) 18 (18.2)  
Antidotes 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.0)  
Antineoplastic Agents 0 (0.0) 6 (8.8) 0 (0.0) 6 (6.1)  
Autonomic Drugs 4 (23.5) 1 (1.5) 0 (0.0) 5 (5.1)  
Blood Formation and Coagulation 1 (5.9) 2 (2.9) 3 (21.4) 6 (6.1)  
Cardiovascular Drugs 2 (11.8) 6 (8.8) 1 (7.1) 9 (9.1)  
Central Nervous System Drugs 3 (17.6) 18 (26.5) 0 (0.0) 21 (21.2)  
Electrolytic, caloric, and water balance 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.0)  
Expectorants and Cough Preparations  1 (5.9) 1 (1.5) 0 (0.0) 2 (2.0)  
Gastrointestinal Drugs 1 (5.9) 4 (5.9) 1 (7.1) 6 (6.1)  
Gold Compounds 0 (0.0) 2 (2.9) 0 (0.0) 2 (2.0)  
Hormones 0 (0.0) 4 (5.9) 0 (0.0) 4 (4.0)  
Anti-infective agents, Cardiovascular drugs 0 (0.0) 0 (0.0) 1 (7.1) 1 (1.0)  
Diagnostic agent, Cardiovascular drugs 1 (5.9) 0 (0.0) 0 (0.0) 1 (1.0)  
Immunosuppressive agents, Antineoplastic agents 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.0)  
All AHFS Classifications 17 (17.2) 68 (68.7) 14 (14.1) 99 0.007 
Reason      
Boxed Warning  5 (29.4) 11 (16.2) 1 (7.1) 17 (17.2) 0.243 
Contraindication 4 (23.5) 12 (17.6) 1 (7.1) 17 (17.2) 0.476 
Warnings 13 (76.5) 49 (72.1) 6 (42.9) 68 (68.7) 0.075 
Precautions 12 (70.6) 39 (57.4) 7 (50.0) 58 (58.6) 0.478 
Dosage administration 3 (17.6) 10 (14.7) 2 (14.3) 15 (15.2) 0.951 
Drug interactions 1 (5.9) 4 (5.9) 1 (7.1) 6 (6.1) 0.983 
Adverse reactions 5 (29.4) 5 (7.4) 1 (7.1) 10 (10.1) 0.055 
Patient Package Insert/Medication Guide 3 (17.6) 18 (26.5) 2 (14.3) 23 (23.2) 0.515 
Pregnancy 0 (0.0) 6 (8.8) 1 (7.1) 7 (7.1) 0.447 
Other changes 3 (17.6) 15 (22.1) 2 (14.3) 20 (20.2) 0.772 
Published reports available 11 (57.9) 36 (48.6) 1 (5.6) 48 (43.2) 0.002 
Original Research PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                        2017, Vol. 8, No. 1, Article 15                         INNOVATIONS in pharmacy   10 
 
 
 
Table 3:  Type of Label Change vs. Publication Status (%) 
 
Label Change Not published Published Total p 
Boxed Warning  9 (15.8) 8 (19.0) 17 (17.2) 0.435 
Contraindication 9 (15.8) 8 (19.0) 17 (17.2) 0.435 
Warnings 36 (63.2) 32 (76.2) 68 (68.7) 0.122 
Precautions 35 (61.4) 23 (54.8) 58 (58.6) 0.324 
Dosage administration 10 (17.5) 5 (11.9) 15 (15.2) 0.316 
Drug interactions 1 (1.8) 5 (11.9) 6 (6.1) 0.048 
Adverse reactions 10 1 10 (11.1) 0.016 
Patient Package Insert/Medication Guide 15 (26.3) 8 (19.0) 23 (23.2) 0.274 
Pregnancy 2 (3.5) 5 (11.9) 7 (7.1) 0.113 
Other changes 11 (19.3) 9 (21.4) 20 (20.2) 0.494 
Total    0.002 
 
 
